Sign in
SuspendedNo phase

Point of Care, Real-Time Urine Metabolomics Test to Diagnose Colorectal Cancers and Polyps in Low-and Middle-Income Countries

Key facts

Who runs it
Obafemi Awolowo University Teaching Hospital
Where
Nigeria1 site in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
People taking part
645 people enrolled
Started
15 Aug 2022
Ended
31 Mar 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Urine PolypDx machine Versus Colonoscopy
Record updated
5 April 2024
Why it stopped
The urine POC device seems not to be promising in colorectal cancer screening

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Patients > 40 years of age with LGI bleeding for more than one week OR
  • Patients who are high risk due to a family history of CRC (first-degree relative)
  • Must be at most 10 years younger than when relative presented with CRC (For example, a patient with a relative diagnosed at age 40 with CRC will be eligible after age 30)
  • Patients with a diagnosis of stage I-III CRC who have no evidence of disease

Who cannot take part

  • Previous diagnosis, treatment, or surgery for any cancer other than CRC
  • Inability to provide a urine sample no fewer than 3 days before colonoscopy
  • Diagnosis of or suspected inflammatory bowel disease
  • Age younger than 40 years with no family history of CRC
  • criteria
  • Patients who are unable to provide written informed consent
  • Any significant medical comorbidities that the anesthesiologist or surgeon determines is a contraindication for colonoscopy in their facility
  • Inability to fully complete the patient satisfaction survey tool

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Study description: the study is a clinical trial aimed at assessing the validity of a point-of-care tool developed for colorectal cancer screening using urine metabolites.

Read full original descriptionShow less

Objectives:

Primary Objective:

In the pilot phase, investigators will field test the POC device in Nigeria on 75 patients who are high-risk for CRC and then validate the urine metabolite signature using a large cohort of 645 patients at high risk for CRC and polyps. This will allow us to determine the sensitivity and specificity of this device and these signatures for CRC and polyps.

Endpoints: the endpoint will be the calculation of the validity (sensitivity and specificity) of the tool. Positive and negative predictive values will also be calculated.

Study population:

Patients > 40 years of age with LGI bleeding for more than one-week OR

* Patients who are high risk due to a family history of CRC (first-degree relative) * Must be at most 10 years younger than when relative presented with CRC (For example, a patient with a relative diagnosed at age 40 with CRC will be eligible after age 30) * Patients with a diagnosis of stage I-III CRC who have no evidence of disease Both males and females will be involved in the study

I. The study will evaluate the validity and acceptability of the POC biosensor device in Nigeria.

Description of sites/facilities enrolling participants: the study will be conducted at Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC) which hosts the head office of African Research Group for Oncology (ARGO). The study will also run concurrently at other ARGO collaborating sites. All the ARGO collaborating sites are tertiary health care facilities with experienced personnel to oversee the study. The pilot study will, however, take place in OAUTHC alone.

Study duration:

The accrual time for the validation study is 2.5 years. Participant Duration: the study will require initial one-time contact. Those that are positive during the screening with the POC biosensor device will be booked for colonoscopy. Hence, for participants with positive results to complete the study may require 2 weeks on average.

The 3 groups in the trial

  • Patients low gastrointestinal tract bleedingExisting treatment, for comparison

    Patients presenting in the surgical outpatients or emergency department with low gastrointestinal tract bleeding

    Treatment: Urine PolypDx machine Versus Colonoscopy

  • Participants who are high risk due to a family history of CRCExisting treatment, for comparison

    First degree relatives of patients diagnosed with colorectal cancer

    Treatment: Urine PolypDx machine Versus Colonoscopy

  • Patients with a diagnosis of stage I-III CRC who have no evidence of diseaseExisting treatment, for comparison

    Patients previously diagnosed of stage I-III CRC and managed in the hospital but are now having no evidence of disease

    Treatment: Urine PolypDx machine Versus Colonoscopy

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
5 April 2024